|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-6-14 05:20 编辑
http://www.reuters.com/article/2011/06/10/gilead-idUSN1019812520110610
Fri Jun 10, 2011 6:53pm EDT
* Subpoena relates to manufacturing, distribution
* Says is cooperating with civil, criminal probe
* Shares fall 2 percent after-hours (Adds background; updates share price)
LOS ANGELES, June 10 (Reuters) - Gilead Sciences Inc(GILD.O), the leading maker of HIV drugs, said it received a subpoena for documents related to its manufacture, quality and distribution practices.
News of the subpoena, from the United States Attorney's Office for the Northern District of California, sent the drugmaker's shares down 2 percent to $39.39 in after-hours trading. The shares dipped 2.3 percent during the regular session.
The request applies to AIDS drugs Atripla, Emtriva, Truvada and Viread, hepatitis drug Hepsera, pulmonary hypertension drug Leitairis and an experimental fixed-dose combination of Truvada and Edurant.
Foster City, California-based Gilead, which brought in revenue of $7.95 billion in 2010, said it is cooperating in the civil and criminal investigation.
Company spokeswoman Cara Miller declined to provide further comment. Gilead said in September it received a warning from the U.S. Food and Drug Administration about manufacturing problems at the San Dimas, California, plant where many of its drugs are made.
The U.S. Attorney's Office did not respond to requests for comment.
Gilead has received two similar subpoenas --in December2006 and August 2009 -- and both were resolved without penalty,said ISI Group analyst Mark Schoenebaum.
"It will likely take years for full resolution ... The worst-case outcome is likely a fine (which could be substantial, depending on the outcome)," he wrote in a note to investors. (Reporting by Deena Beasley; editing by Robert MacMillan,Matthew Lewis and Andre Grenon)
|
|
发表于 2011-6-14 05:16